Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Subarachnoid Hemorrhage
NCT02872857Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Sep 2016
- Primary completion
- Jul 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galantamine in subarachnoid hemorrhage (SAH) (3 arms), sponsored by UTHealth Houston. Primary endpoints: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event at 90 days, Mortality at 90 days and 1 more. Started Sep 2016; status: completed.
02
Drugs
galantamine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT02872857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872857.